9 terminated, 8 completed, 5 recruiting, 2 active not recruiting. 27 Phase 2, 7 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 27 | Terminated 9, Completed 8, Recruiting 5, Active not recruiting 2, Withdrawn 2, Unknown 1 |
| Phase 1 | 7 | Completed 3, Withdrawn 2, Terminated 1, Unknown 1 |
| Phase 3 | 1 | Completed 1 |
Follow Cancer of the Breast: new trials by email Literature Review of Cancer of the Breast trials Research Report on Cancer of the Breast
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder Psilocybin therapy - Adjustment Disorder, Adjustment Disorder With Anxious Mood | Phase 2 | Recruiting | Psyence Australia Pty Ltd | 87 | 2025-10-01 | 2026-10-29 |
| DAANCE FOR CHEMOTHERAPY-INDUCED NEUROPATHY Tango - Cancer of the Breast, Chemotherapy-induced Neuropathy | Phase 2 | Recruiting | Ohio State University Comprehensive Cancer Center | 140 | 2025-02-19 | 2026-10-09 |
| NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer VENTANA MIB-1 Ki67 assay, Oncotype DX® Recurrence Score, PAM50-based Prosigna breast cancer gene signature assay - Breast Cancer, Cancer of the Breast | Phase 2 | Recruiting | Washington University School of Medicine | 81 | 2024-05-30 | 2026-04-13 |
| A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer BC1 cell line, Bria-OTS regimen and CPI (tislelizumab), Bria-OTS regimen and CPI (tislelizumab) expansion cohort - Breast Cancer, Breast Tumor | Phase 1 / Phase 2 | Unknown | BriaCell Therapeutics Corporation | 18 | 2024-05-29 | 2024-08-26 |
| Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC NUV-422, Fulvestrant - Advanced Breast Cancer, Metastatic Breast Cancer | Phase 1 / Phase 2 | Withdrawn | Nuvation Bio Inc. | 2022-09-01 | 2023-07-11 | |
| Real-time Intraoperative Breast Cancer Visualization for Margin Assessment LS301, Cancer Vision Goggles and standard fluorescence imaging systems, Surgery - Breast Cancer, Cancer of the Breast | Phase 1 / Phase 2 | Terminated | Samuel Achilefu | 9 | 2020-02-18 | 2025-08-17 |
| Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score FACT-B, Goserelin, Anastrozole - Breast Cancer, Cancer of Breast | Phase 2 | Recruiting | Washington University School of Medicine | 50 | 2017-01-17 | 2026-07-27 |
| MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors MEDI4736 - Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer | Phase 2 | Terminated | Washington University School of Medicine | 4 | 2016-09-12 | 2018-11-06 |
| Shave Margins in Breast Conservation Therapy Breast-conserving surgery (BCS), Cavity shave margins (CSM), BREAST-Q Questionnaire - Breast Cancer, Cancer of Breast | Phase 2 | Terminated | Washington University School of Medicine | 81 | 2016-06-13 | 2020-06-25 |
| Inhibiting Fatty Acid Synthase to Improve Efficacy of Neoadjuvant Chemotherapy Omeprazole - Cancer of the Breast | Phase 2 | Completed | Kathy Miller | 42 | 2015-11-12 | 2021-12-15 |
| CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448) Seviteronel - Cancer of the Breast, Breast Cancer | Phase 1 / Phase 2 | Completed | Innocrin Pharmaceutical | 175 | 2015-08-01 | 2019-02-01 |
| Combination of Carboplatin, Eribulin Mesylate, and E7449 in BRCA-Related Cancers Carboplatin, Eribulin, E7449 - Cancer of the Breast | Phase 1 / Phase 2 | Withdrawn | The University of Texas Health Science Center at San Antonio | 2015-04-01 | 2015-08-25 | |
| Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) nab-Paclitaxel, Carboplatin, Gemcitabine - Breast Tumor, Breast Cancer | Phase 2 / Phase 3 | Completed | Celgene | 191 | 2013-09-26 | 2019-02-21 |
| Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer Proton Radiotherapy - Breast Cancer, Breast Neoplasm | Phase 2 | Recruiting | Proton Collaborative Group | 132 | 2013-02-01 | 2026-09-29 |
| Proton Radiation for Stage II/III Breast Cancer Proton Radiotherapy - Breast Cancer, Breast Neoplasm | Phase 2 | Active not recruiting | Proton Collaborative Group | 220 | 2013-02-01 | 2026-09-29 |
| Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer Eribulin, Doxorubicin, Cyclophosphamide - Breast Neoplasms, Breast Cancer | Phase 2 | Terminated | Emory University | 7 | 2011-11-01 | 2016-10-03 |
| A Study of Lapatinib in Combination With Everolimus in Patients With Advanced, Triple Negative Breast Cancer Lapatinib and Everolimus - Breast Neoplasms, Breast Cancer | Phase 2 | Terminated | Emory University | 5 | 2010-12-01 | 2014-09-22 |
| Study of Pralatrexate in Female Patients With Previously-treated Breast Cancer Pralatrexate Injection, Vitamin B12, Folic Acid - Breast Cancer, Breast Tumors | Phase 2 | Completed | Acrotech Biopharma Inc. | 22 | 2010-03-01 | 2020-01-07 |
| Trial Using Docetaxel Cytoxan in Breast Cancers With High Recurrence Scores Docetaxel with Cytoxan, Dexamethasone - Breast Neoplasms, Breast Cancer | Phase 2 | Terminated | Emory University | 23 | 2009-04-01 | 2017-08-31 |
| Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer IPI-504, Trastuzumab - Breast Cancer, HER2 Positive Breast Cancer | Phase 2 | Terminated | Infinity Pharmaceuticals, Inc. | 29 | 2009-03-01 | 2012-12-11 |
Showing 20 of 27. Sign in to see all of them.
Breast Neoplasms (27) · Triple Negative Breast Neoplasms (3) · Kidney Neoplasms (2) · Neoplasms (2) · Pancreatic Neoplasms (2) · Adjustment Disorders (1) · Breast Neoplasms, Male (1) · Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1) · Melanoma (1) · Neoplasm Metastasis (1) · Ovarian Neoplasms (1) · Prostatic Neoplasms (1) · Stomach Neoplasms (1)
Breast Diseases (27) · Neoplasms by Site (27) · Skin Diseases (27) · Skin and Connective Tissue Diseases (27) · Neoplasms (25) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Endocrine Gland Neoplasms (2) · Endocrine System Diseases (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Gastrointestinal Diseases (2) · Gastrointestinal Neoplasms (2) · Genital Diseases (2) · Genital Diseases, Female (2)
Anastrozole (3) · Carboplatin (2) · Cyclophosphamide (2) · Docetaxel (2) · Fulvestrant (2) · Gemcitabine (2) · Trastuzumab (2) · eribulin (2) · 10-propargyl-10-deazaaminopterin (1) · 130-nm albumin-bound paclitaxel (1) · Albumin-Bound Paclitaxel (1) · Aryl Hydrocarbon Receptor Nuclear Translocator (1) · Bevacizumab (1) · Calcium Dobesilate (1) · Dexamethasone (1)
Washington University School of Medicine (4) · Emory University (3) · Proton Collaborative Group (2) · University of Arkansas (2) · Acrotech Biopharma Inc. (1) · BriaCell Therapeutics Corporation (1) · Celgene (1) · Eli Lilly and Company (1) · Georgetown University (1) · Infinity Pharmaceuticals, Inc. (1) · Innocrin Pharmaceutical (1) · Kathy Miller (1) · NeuTec Pharma (1) · Nuvation Bio Inc. (1) · Ohio State University Comprehensive Cancer Center (1)
United States (23) · Australia (2) · France (2) · Spain (2) · Austria (1) · Brazil (1) · Canada (1) · Czechia (1) · Germany (1) · Greece (1) · Hungary (1) · India (1) · Italy (1) · Poland (1) · Portugal (1)
Andrew Chang, MD (1) · Anna Pluzanska, MD (1) · Claudine Isaacs, M.D. (1) · Daniela Ochoa, MD (1) · Deborah Farr, M.D. (1) · Elisavet Paplomata, MD (1) · Eugen Hug, MD (1) · Garry Weems, PharmD (1) · Giuseppe Del Priore, MD, MPH (1) · Ileana Elias, M.D. (1) · Julie Margenthaler, M.D. (1) · Kathy Miller, MD (1) · Keerthi Gogineni, MD, MSHP (1) · Lise B Worthen-Chaudhari, PhD, MFA, CMES (1)
PMID 18471751, PMID 19800452, PMID 23018481, PMID 23948301, PMID 31849532, PMID 40671809, PMID 41723535
2008 (1), R01AG084676 (1)